Investigation of Clofarabine in Acute Leukemias

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The goals and objectives of this project are to evaluate the antileukemic activity of the investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic phases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas
• Treatments: Clofarabine

Criteria

• Patient is diagnosed with AML, ALL, myelodysplastic syndrome (MDS), and CML in transformation (includes CML-blastic phase and CML-accelerated phase).

• No prior chemo-, immuno-, or radio-therapy for 2 weeks before entering the study, unless progressive life-threatening leukemia as judged by the treated physician.

• Adequate liver function (bilirubinmg%).

• Pregnant and lactating females not eligible.

• Zubrod performance status 0-2

• Adequate cardiac status

• No life-threatening conditions (e.g. infections) which may cause death within 3 weeks.